Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

• Status: Completed
• Trial end date: 2016-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Subjects achieving a clinical response in study OX4218s with a biomarker reduction or symptom response are eligible to enroll in this rollover study to continue once every three weeks fosbretabulin infusions for up to one year.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mateon Therapeutics
• Treatments: Combretastatin; Fosbretabulin

Criteria

Inclusion Criteria:

• Subject has been treated in the OXiGENE-sponsored Phase 2 study OX4218s

Exclusion Criteria:

• Subject has not received fosbretabulin treatment in the study OX4218s